Cresilon, Inc. is a medical device company that develops and commercializes innovative wound closure and hemostatic products. The company's flagship product, Vetigel, is a plant-based hemostatic gel that is designed to stop bleeding in animals. Vetigel is made from plant-derived polymers that mimic the body's extracellular matrix, which allows it to adhere to tissue and stop bleeding within seconds. Cresilon is also developing a human version of Vetigel, which is currently in clinical trials. The company was founded in 2013 and is headquartered in New York City.